Cardio Diagnostics Holdings Inc Dossier
Qualitative Analysis
Business overview
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) is an artificial intelligence-powered precision cardiovascular medicine company. Founded in 2017 and headquartered in Chicago, Illinois, the company develops and commercializes clinical tests based on genetics and epigenetics to detect and assess the risk of coronary heart disease (CHD). Its core product offerings include Epi+Gen CHD™, a clinical blood test designed to evaluate an individual's three-year risk of a symptomatic CHD event (such as a heart attack), and PrecisionCHD™, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. These tests are supported by the company's proprietary AI-driven Integrated Genetic-Epigenetic Engine and are coupled with its Actionable Clinical Intelligence platform to provide personalized insights for tailored clinical decision-making.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Partnering with Aimil Ltd. and Dr. Lal PathLabs to integrate and launch the PrecisionCHD™ test across Dr. Lal PathLabs' extensive clinical laboratory network in India.
Expected impact: Establishes the company's first commercial footprint outside the United States, targeting a high-prevalence cardiovascular disease market.
Collaborating with community organizations, such as the Southdale YMCA in Edina, Minnesota, to offer discounted AI-powered cardiovascular testing and educational events.
Expected impact: Increases local community access to Epi+Gen CHD™ and PrecisionCHD™ tests while driving brand awareness and proactive heart health management.
Collaborating with AGEPHA Pharma to validate a precision-guided approach to treating inflammation-driven coronary heart disease using the PrecisionCHD™ blood test alongside AGEPHA's FDA-approved LODOCO® medication.
Expected impact: Demonstrates the clinical utility of the company's epigenetic tests in monitoring treatment response over time, potentially driving pharmaceutical channel adoption.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Marks Cardio Diagnostics' first international expansion, leveraging Dr. Lal PathLabs' network of over 290 clinical laboratories and 300 MD pathologists to commercialize PrecisionCHD™ in India.
Terms: Not publicly disclosed
Aims to validate the use of PrecisionCHD™ to assess patient response to AGEPHA's FDA-approved anti-inflammatory cardiovascular drug, LODOCO®.
Terms: Not publicly disclosed
Expands community-based access to AI-powered cardiovascular testing and heart health education in Minnesota.
Terms: Discounted testing rates offered to YMCA members and local residents